Business

Around the Region

Cubist’s antibiotic on fast track

Federal regulators have granted fast-track review status­ of several uses for an experimental­ antibiotic drug developed by Cubist Pharmaceuticals Inc.

The Lexington company said it got fast-track status from the Food and Drug Administration­ for ceftolozane/tazobactam, also known as CXA-201, in treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, along with complicated urinary tract infections.

Advertisement

In February, the FDA granted fast-track status for CXA-201 in treating complex intra-abdominal infections.

If the drug is approved under the priority review, Cubist will get a five-year extension of exclusivity under an antibiotics incentive law signed by President Obama last year.

Robert Weisman

Robert Weisman can be reached at weisman@globe.com. Follow him on Twitter @GlobeRobW.
Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com